

Acid responsive Molybdenum (Mo)-based nanoparticles inhibit cGAS-STING signaling pathway for sepsis therapy

Xinyu Wang ^{1, #}, Qingbin He ^{1, #}, Lining Wang ², Chengzhilin Li ¹, Wenyu Zhang ¹ ,

Zhonghou Rong ^{1, *}, Qingqing Yin ^{1, *}, Yingchun Zhao ^{1, *}

¹ Shandong Provincial Hospital, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China

² Department of Oncology No.1, Rushan People's Hospital, Rushan 264500, Shandong, China

These authors contributed equally to this work.

Corresponding Author:

Yingchun Zhao

Shandong Provincial Hospital, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China

zhaoyingchun26@163.com

Qingqing Yin

*Shandong Provincial Hospital, Medical Science and Technology Innovation Center,
Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan
250117, Shandong, China*

yinqingqing@sdfmu.edu.cn

Zhonghou Rong

*Shandong Provincial Hospital, Medical Science and Technology Innovation Center,
Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan
250117, Shandong, China*

15966067110@163.com




Figure S1. Size and Zeta potential of DMSN, DMSNM, DMSNM@C-178 and DMSNM@C-178/PAA. Data are expressed as mean \pm SD (n=3).




Figure S2. Raman spectrum of DMSN and DMSNM.




Figure S3. Flow cytometry analysis of cellular uptake of 100 $\mu\text{g/mL}$ FITC-loaded DMSNM@C-178 in RAW264.7 cells at different times within 24 hours.




Figure S4. Detection of ROS-scavenging ability of 100 $\mu\text{g/mL}$ DMSNM@C-178 NPs in RAW264.7 cells under different treatment in LPS and H₂O₂-stimulated by flow cytometry analysis Data are expressed as mean \pm SD (n=3). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure S5. Western blot analysis of protein levels in RAW264.7 cells after treatment with PBS, DMSN, DMSNM, DMSNM@C-178 after LPS-stimulated. Data are expressed as mean \pm SD (n=3). * $p<0.05$, ** $p<0.01$, *** $p<0.001$.




Figure S6. Blood biochemical and hematological analysis. “Control” represents the healthy mice; “NPs” represents the mice intravenously injected with DMSNM@C-178/PAA nanoparticles after 14 days.

The standard hematology markers include hematocrit (HCT), hemoglobin (HGB), lymphocyte absolute value (Lym), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), neutrophil absolute value (Neu), platelets (PLT), red blood cells (RBC), white blood cells (WBC).

The liver status is reflected by the levels of albumin (ALB), alanine transaminase (ALT), Creatinine (Cr), and total protein (TP), whilst kidney function is evaluated by measuring uric acid (UA) and Urea markers.




Figure S7. Hematoxylin and eosin (H&E) staining of heart, spleen, intestines and stomach. “Control” represents the healthy mice; “NPs” represents the mice intravenously injected with DMSNM@C-178/PAA nanoparticles after 14 days. Scale bar is 100 μm .




Figure S8. (A) Fluorescence imaging of heart, liver, spleen, lung and kidney 24 hours post-injection of DMSNM@C-178/PAA after LPS-challenge 1 hour. (B) The concentrations of Mo ions in mouse tissues were measured via ICP-MS analysis by DMSNM@C-178/PAA administration after LPS-challenge 1 hour. The results were presented as the percentage of the injected dose per gram of tissue (% ID/g).




Figure S9. The levels of ALT (alanine transferase) and Urea of septic mice and the mice intravenously injected with DMSNM@C-178/PAA nanoparticles. Data are expressed as mean \pm SD (n=3). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.